Biocartis has secured FDA premarket approval for its Idylla CDx MSI test, developed in partnership with Bristol Myers Squibb. This automated, cartridge-based test rapidly identifies microsatellite instability-high colorectal cancer patients eligible for immunotherapy treatment with BMS's Opdivo, alone or combined with Yervoy, as demonstrated in the CheckMate-8HW trial. The test's quick turnaround under three hours enhances precision medicine by enabling timely and targeted therapeutic decisions in colorectal cancer management.